SOURCE: Insight Pharma Reports

Insight Pharma Reports

June 08, 2016 11:30 ET

Insight Pharma Reports: Biomanufacturing Capacity Strategies: Developing a Flexible, Scalable and Lean Biomanufacturing System

Overview of Single-Use Biomanufacturing Techniques and Trends, Outlining the Importance of Reactive Biomanufacturing

NEEDHAM, MA--(Marketwired - June 08, 2016) - Insight Pharma Reports, a division of Healthtech Publishing, provides the life science sciences community the report entitled: Biomanufacturing Capacity Strategies: Developing a Flexible, Scalable and lean Biomanufacturing system which focuses on the need for a more reactive and dynamic biomanufacturing approach than is the current industry standard.

Biomanufacturing is common practice in the life sciences industry and has been continually developed and improved for the last two decades. However, as blockbuster drugs reach the end of their patents, treatment is evolving to become more patient-centric and personalized. The mapping of the human genome has allowed for sophisticated and effective new genetic markers and diagnostic methods to be developed, meaning that personalized medicine is becoming a reality. This has a direct impact on manufacturing, with long-term expected production paradigm shifts in the shape of near-patient manufacturing.

In addition to covering background information on biomanufacturing and capacity approaches, the Biomanufacturing Capacity Strategies: Developing a Flexible, Scalable and lean Biomanufacturing system report will highlight several technologies, methodologies, and business strategies that can be implemented to improve the capacity and flexibility of biomanufacturing.

Included in this Report:

  • Detailed the history of biomanufacturing development and the direction for the coming decade
  • Overview of single-use biomanufacturing techniques and trends, outlining the importance of reactive biomanufacturing
  • Insight into the Ebola vaccine clinical development, as well as the validation process.
  • Specific capacity-enhancing approaches ranging from technology solutions to business strategy
  • Examine the overarching industry pressures that are driving capacity needs, the subsequent regulatory compliance, and where the biggest efficiency and productivity savings can be realized.
  • Explore the scale-up of biomanufacturing processes to serve commercial scale production, which is currently a major limiting factor in the maturity of this field, and how commercialization of certain therapeutics and regenerative medicines is severely limited by the lack of progression here.
  • Ventures into the realm of lean thinking and continuous manufacturing methodologies and their application in the field of biomanufacturing with a secondary look at the potential of combining modular facilities with disposable biomanufacturing systems and the technical requirements and advances.
  • Details a considerable amount with regard to technology transfer and the specific issues relating to biomanufacturing, and outlines some solutions and new approaches to knowledge transfer
  • Takes a wider view of the context, importance, and impact of biomanufacturing and its capacity to provide a solution to several biotechnology industry challenges.
  • Provides insight into the field of personalized medicine, cell and gene therapies, and commercial-scale manufacturing vs. near-patient production and the predicted paradigm shift.
  • Interviews with:
    • Tony Hitchcock, Technical Director, Cobra Biologics
    • Jerold Martin, Sr. V.P. Global Scientific Affairs, Biopharmaceuticals, Pall Corporation
    • Arnaud Schmutz, General Manager, Sourcin
    • Nigel Smart, Managing Partner, Smart Consulting Group
    • Keith Thompson, CEO, Cell Therapy Catapult

For more information on these reports visit: InsightPharmaReports.com/Biomanufacturing-Capacity-Strategies-Report

About Insight Pharma Reports (www.insightpharmareports.com)
Insight Pharma Reports, a division of Healthtech Publishing, is the premier life sciences information provider offering unparalleled coverage of key issues in drug discovery and development. The reports are used by leading pharmaceutical, biotech, diagnostic, and other life science companies to keep abreast of the latest developments in pharmaceutical R&D and their potential applications and business impacts. The reports are written by experts in consulting and industry, and are supported by hundreds of hours of primary and secondary research. Insight Pharma Reports provide comprehensive coverage of salient issues in a concise, well-organized format.

About Healthtech Publishing (www.healthtechpublishing.com)
Healthtech Publishing, a division of Cambridge Healthtech Institute, provides the life science communities with business critical intelligence through research reports and digital news, helping decision makers to gain competitive advantage and make strategic decisions. Our portfolio consists of Insight Pharma Reports' vast research reports collection and three niche digital subscription products: Bio-IT World, Clinical Informatics News and Diagnostics World.

Contact Information